| Literature DB >> 36193543 |
Yanyi Liu1, Zhuang Liu1, Xin Li1, Ning Li1, Ruirui Kong1, Yiyao Jiang2, Shenglin Ge1, Chengxin Zhang1.
Abstract
Robotic surgery can provide less surgical trauma than conventional surgery, but differences between robotic and thoracoscopic surgery for atrial septal defect (ASD) repair are not well documented. To explore whether ASD can be repaired by thoracoscopic surgery or robotic surgery, which procedure is less invasive, and the difference in outcomes between these two procedures, this article studies 160 patients undergoing ASD repair at our institution. Sixty-five patients underwent total thoracoscopic surgery and 95 patients underwent total endoscopic robotic surgery. Propensity score matching yielded 64 well-matched patient pairs. Surgical data and early postoperative outcomes between the two matched groups were analyzed and compared. The results show that thoracoscopic and robotic surgery to repair ASD are both safe and reliable, and the early curative effect is good. However, regardless of similar complication rates, robotic surgery has a shorter time, less postoperative drainage, and faster recovery than thoracoscopic surgery.Entities:
Year: 2022 PMID: 36193543 PMCID: PMC9525788 DOI: 10.1155/2022/5371493
Source DB: PubMed Journal: Emerg Med Int ISSN: 2090-2840 Impact factor: 1.621
Patient baseline characteristics before propensity matching.
| Characteristics | Thoracoscopic group | Robotic group |
|
|---|---|---|---|
| ( | ( | ||
| Male ( | 23(35.4) | 3233.7 | 0.824 |
| Age (y, mean ± SD) | 39.69 ± 14.82 | 37.88 ± 16.12 | 0.473 |
| Weight (kg, mean ± SD) | 59.33 ± 10.77 | 58.06 ± 10.79 | 0.464 |
| Diabetes ( | 0(0.0) | 8(8.4) | 0.042 |
| Hypertension ( | 5(7.7) | 5(5.3) | 0.771 |
| Current smoke ( | 2(3.1) | 5(5.3) | 0.787 |
| Congestive heart failure ( | 1(1.5) | 6(6.3) | 0.290 |
| Atrial fibrillation ( | 4(6.2) | 5(5.3) | 1.000 |
| Systemic embolism ( | 0(0.0) | 0(0.0) | NA |
| Defect diameter (cm, mean ± SD) | 2.88 ± 0.77 | 2.67 ± 0.89 | 0.128 |
| Defect type ( | 0.945 | ||
| Fossa ovalis type | 38(58.5) | 54(56.8) | |
| SVC type | 3(4.6) | 5(5.3) | |
| IVC type | 21(32.3) | 29(30.5) | |
| Mixed type | 3(4.6) | 7(7.4) | |
| LVEF (%, mean ± SD) | 62.45 ± 4.66 | 61.74 ± 4.36 | 0.328 |
| PASP (mmHg, mean ± SD) | 51.02 ± 10.98 | 52.41 ± 11.82 | 0.452 |
| Creatinine ( | 63.69 ± 15.37 | 62.86 ± 11.90 | 0.714 |
| With PAPVC ( | 2(3.1) | 7(7.4) | 0.419 |
SVC type: superior vena cava type; IVC type: inferior vena cava type; LVEF: left ventricular ejection fraction; PASP: pulmonary artery systolic pressure; and PAPVC: partial anomalous pulmonary venous connection.
Patient baseline characteristics after propensity matching.
| Characteristics | Thoracoscopic group | Robotic group |
|
|---|---|---|---|
| ( | ( | ||
| Male ( | 23(35.9) | 21(32.8) | 0.710 |
| Age (y, mean ± SD) | 39.64 ± 14.93 | 36.86 ± 15.91 | 0.310 |
| Weight (kg, mean ± SD) | 59.40 ± 10.84 | 57.91 ± 9.42 | 0.407 |
| Diabetes ( | 0 (0.0) | 0 (0.0) | NA |
| Hypertension ( | 5 (7.8) | 3 (4.0) | 0.715 |
| Current smoke ( | 2 (3.1) | 4 (6.3) | 0.676 |
| Congestive heart failure ( | 1 (1.6) | 2 (3.1) | 1.000 |
| Atrial fibrillation ( | 4 (6.3) | 2 (3.1) | 0.676 |
| Systemic embolism ( | 0 (0.0) | 0 (0.0) | NA |
| Defect diameter (cm, mean ± SD) | 2.87 ± 0.77 | 2.65 ± 0.80 | 0.111 |
| Defect type ( | 0.780 | ||
| Fossa ovalis type | 38 (59.4) | 39 (60.9) | |
| SVC type | 3 (4.7) | 4 (6.3) | |
| IVC type | 20 (31.3) | 16 (25.0) | |
| Mixed type | 3 (4.7) | 5 (7.8) | |
| LVEF (%, mean ± SD) | 62.17 ± 4.13 | 62.06 ± 4.55 | 0.889 |
| PASP (mmHg,mean ± SD) | 50.95 ± 11.05 | 50.81 ± 10.82 | 0.942 |
| Creatinine ( | 63.92 ± 15.38 | 62.83 ± 11.32 | 0.650 |
| With PAPVC ( | 2 (3.1) | 5 (7.8) | 0.437 |
SVC type: superior vena cava type; IVC type: inferior vena cava type; LVEF: left ventricular ejection fraction; PASP: pulmonary artery systolic pressure; and PAPVC: partial anomalous pulmonary venous connection.
Perioperative details (propensity-matched groups).
| Thoracoscopic group | Robotic group |
| |
|---|---|---|---|
| ( | ( | ||
| Operation time (min, median (IQR)) | 300.00 (250.00, 373.75) | 210.00(180.00, 240.00) | <0.001 |
| CPB time (min, median (IQR)) | 123.50 (95.25, 164.50) | 74.50 (64.25, 92.00) | <0.001 |
| Surgical closure technique | 0.244 | ||
| Pericardial patch | 61 (95.3) | 64 (100.0) | |
| Primary suturing | 3 (4.7) | 0 (0.0) | |
| Concomitant PAPVC repair | 2 (3.1) | 5 (7.8) | 0.453 |
| ICU stay (h, median (IQR)) | 22.00 (20.00, 46.00) | 19.00 (18.00, 24.00) | 0.001 |
| Mechanical ventilation time (h, median (IQR)) | 6.75 (4.50, 15.00) | 4.00 (3.00, 6.75) | 0.02 |
| Postoperative hospital-stay (d, median (IQR)) | 9.00 (7.00, 13.00) | 8.00 (7.00, 9.00) | 0.025 |
| Thoracic drainagea (ml, median (IQR)) | 277.50 (151.25, 460.75) | 207.50 (101.25, 300.00) | 0.001 |
| Total RBC usage (U, median (IQR)) | 3.00 (0.00, 4.00) | 0.00 (0.00, 0.00) | <0.001 |
| Total hospital costs | 1.33 (1.13, 1.76) | 1.49 (1.34, 1.69) | 0.097 |
| (×104$, median (IQR)) |
a:the volume of thoracic drainage in the first 24 hours after operation; CPB: cardiopulmonary bypass; ICU: intensive care unit; and PAPVC: partial anomalous pulmonary venous connection.
In-hospital complications (propensity-matched groups).
| Thoracoscopic group | Robotic group |
| |
|---|---|---|---|
| ( | ( | ||
| In-hospital mortality ( | 0 (0.0) | 0 (0.0) | NA |
| New-onset arrhythmia ( | 4 (6.3) | 2 (3.1) | 0.687 |
| Atrial fibrillation | 4 (6.3) | 1 (1.6) | |
| Supraventricular tachycardia | 0 (0.0) | 1 (1.6) | |
| Systemic embolism ( | 4 (6.3) | 1 (1.6) | 0.375 |
| Stroke | 2 (3.1) | 1 (1.6) | |
| Peripheral embolism | 2 (3.1) | 0 (0.0) | |
| Reoperation for bleeding ( | 1 (1.6) | 0 (0.0) | NA |
| DMV ( | 7 (10.9) | 3 (4.7) | 0.344 |
| Residual shunt | 1 (1.6) | 1 (1.6) | 1.000 |
| Intraoperative (TEE) | 0 (0.0) | 0 (0.0) | NA |
| Before discharge (TTE) | 1 (1.6) | 1 (1.6) | 1.000 |
| Pneumonia ( | 3 (4.7) | 1 (1.6) | 0.625 |
| Renal failure ( | 0 (0.0) | 1 (1.6) | NA |
| Pneumothorax ( | 1 (1.6) | 1 (1.6) | 1.000 |
DMV: delayed mechanical ventilation (>24 h).
Figure 1The Kaplan–Meier survival curve. Over 6 months of follow-up, freedom from MACCEs for matched thoracoscopic group and robotic group were 83.6% and 93.4%, respectively (P=0.093).